Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
Messoud Ashina*, Stewart Tepper, Jan Lewis Brandes, Uwe Reuter, Guy Boudreau, David Dolezil, Sunfa Cheng, Feng Zhang, Robert Lenz, Jan Klatt, Daniel D. Mikol
Dive into the research topics of 'Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study'. Together they form a unique fingerprint.